Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN

Condition:   HNSCC
Intervention:   Drug: Durvalumab
Sponsors:   Groupe Oncologie Radiotherapie Tete et Cou;   UNICANCER;   Center Eugene Marquis
Not yet recruiting

https://ift.tt/2Jtt9zY